CBD can be light at the tunnel’s end for US cannabis and pharma firms

A series of year-end results from cannabis-related companies in the US demonstrates the importance of CBD to the bottom line, with volatility in much of the rest of the cannabis and pharmaceutical sectors ...

Restricted content. Do you want to read more?